Market Overview

Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

Penny stock Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was sinking lower Tuesday after the nanocap biotech's announcement concerning a paper published by independent investigators in the Journal of Clinical Oncology regarding the protein expression and efficacy of a drug to treat HR-positive and HER-negative breast cancer.

What Happened

Cyclacel said the study findings identified overexpression of the protein cyclin E1 as being responsible for breast cancer escaping the effect of Pfizer Inc. (NYSE: PFE)'s palbociclib — a CDK4/6 inhibitor —plus fulvestrant.

How does this finding help Cyclacel? Cyclacel's clinical-stage candidate CYC065, its second-gen CDK2/9 inhibitor, targets CDK2/cyclin E complex and is proposed as a potential therapeutic option to prevent early progression on CDK4/6 inhibitor.

After rising as high as 24 percent intraday Monday, the stock gave back all its gains and ended flat at 95 cents.

Why It's Important

Cyclacel has initiated a Phase 1 trial evaluating its CYC065 in combination with venetoclax in patients with relapsed/refractor CLL, while it reported data from a Phase 1 Part 1 study of CYCO65 as a monotherapy in advanced solid tumors at a conference in 2018.

At last check, Cyclacel shares were sliding 7.8 percent to 88 cents.

Related Links:

The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Posted-In: breast cancer Journal of Clinical OncologyBiotech News Trading Ideas Best of Benzinga


Related Articles (CYCC + PFE)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

More Tumult For The Turkey ETF

Model N Has Happy Customers And Good Pipeline Momentum, Oppenheimer Says